Rhenman & Partners Asset Management AB Has $2.26 Million Holdings in Medpace Holdings, Inc. (NASDAQ:MEDP)

Rhenman & Partners Asset Management AB decreased its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 9.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 6,800 shares of the company’s stock after selling 700 shares during the period. Rhenman & Partners Asset Management AB’s holdings in Medpace were worth $2,259,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in the stock. Proficio Capital Partners LLC increased its stake in Medpace by 34,497.4% in the 4th quarter. Proficio Capital Partners LLC now owns 242,528 shares of the company’s stock valued at $80,575,000 after buying an additional 241,827 shares during the period. Raymond James Financial Inc. purchased a new position in shares of Medpace during the 4th quarter valued at $78,144,000. Norges Bank acquired a new position in shares of Medpace in the fourth quarter worth $69,859,000. GW&K Investment Management LLC increased its stake in shares of Medpace by 93.9% in the fourth quarter. GW&K Investment Management LLC now owns 275,460 shares of the company’s stock worth $91,516,000 after acquiring an additional 133,379 shares during the last quarter. Finally, Wellington Management Group LLP raised its holdings in shares of Medpace by 36.0% during the third quarter. Wellington Management Group LLP now owns 415,255 shares of the company’s stock worth $138,612,000 after acquiring an additional 109,886 shares in the last quarter. 77.98% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

MEDP has been the topic of a number of recent research reports. Leerink Partnrs upgraded Medpace to a “hold” rating in a research note on Monday, March 24th. Robert W. Baird boosted their price target on Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a research note on Monday, January 27th. Finally, Leerink Partners began coverage on shares of Medpace in a research report on Monday, March 24th. They set a “market perform” rating and a $330.00 price objective on the stock. Nine investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Medpace currently has an average rating of “Hold” and a consensus target price of $376.30.

Medpace Price Performance

Shares of MEDP opened at $287.11 on Friday. The company has a market capitalization of $8.75 billion, a PE ratio of 22.73, a price-to-earnings-growth ratio of 3.81 and a beta of 1.45. Medpace Holdings, Inc. has a one year low of $282.42 and a one year high of $459.77. The company’s fifty day moving average price is $331.56 and its 200 day moving average price is $337.60.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Monday, February 10th. The company reported $3.67 EPS for the quarter, topping analysts’ consensus estimates of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. Analysts anticipate that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.